Atrial fibrillation risk
Can omega-3 treatment increase atrial fibrillation risk?
High-dose cardiovascular trials have reported more atrial fibrillation. A 2026 synthesis suggests the signal is concentrated in high-risk patients receiving higher doses.
Updated September 24, 2026 · Editorial attribution: PV Griscom, M.Sc. · Independent clinical review pending
The question behind the headline
2026 meta-analysis of 35 trials, 114,592 participants, examining new-onset atrial fibrillation.
What the finding does—and doesn’t—tell us
Dose, cardiovascular risk and follow-up matter. Absence of a significant signal in a subgroup does not establish zero risk. Discuss prescription-dose use with a clinician.
Read the underlying research.
- Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials including 114 592 Individuals. · 2026 ↗
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. · 2019 ↗
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. · 2020 ↗
Selected sources, not an exhaustive reference list. Research record or abstract screening only; full-text efficacy appraisal is pending. Source publication dates may precede this page’s update date.
Three questions to take forward
- Was the study population similar to the person or situation I have in mind?
- Did it measure an outcome people feel or experience, or only a laboratory marker?
- How do formulation, usual care, absolute benefit and adverse effects change the interpretation?
Study doses describe experiments; they are not personal dosing advice. Explore safety and limitations ↗